Five local drugmakers have obtained approval for medicines that changed the dosing of Pfizer’s Lyrica (ingredient: pregabalin), a neuropathic pain reliever, from twice daily to once daily.
|Pfizer’s neuropathic pain reliever Lyrica Cap.|
The Ministry of Food and Drug Safety on Friday allowed LG Chem, Hanlim Pharmaceutical, GL PharmTech, Daewon Pharmaceutical, and Crown Pharm to sell nine sustained-release products that used pregabalin as the main ingredient.
The nine medicines changed the dosing of Pfizer’s Lyrica, which comes in three dosing – 75mg, 150mg, and 300mg. Patients take Lyrica twice a day.
However, patients can take the sustained-release drugs once daily. Physicians prescribe Lyrica as a monotherapy or as a combination therapy with treatment for diabetes or shingles.
Neuropathic pain occurs due to damage or functional abnormality of the nervous system. The pain is refractory and chronically long-lasting.
The chronic neuropathic pain lowers the quality of life of patients and causes a sleep disorder, depression, and social maladjustment.
<© Korea Biomedical Review, All rights reserved.>